BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2015 6:12:00 PM | Browse: 202 | Download: 471
Publication Name World Journal of Hepatology
Manuscript ID 15818
Country of Manuscript Source France
2014-12-10 14:01
Peer-Review Started
2014-12-10 16:46
To Make the First Decision
2015-02-07 15:01
Return for Revision
2015-02-11 11:22
2015-03-15 02:09
Second Decision
2015-08-20 16:23
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2015-08-31 15:09
Articles in Press
2015-08-31 15:09
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-09-07 09:47
Publish the Manuscript Online
2015-09-15 18:11
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Review
Article Title Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging
Manuscript Source Invited Manuscript
All Author List Mohamed Bouattour, Audrey Payancé and Johanna Wassermann
Funding Agency and Grant Number
Correspondence To Dr. Mohamed Bouattour, Department of Hepatology, Beaujon University Hospital (AP-HP - Paris 7 Diderot), 100 Boulevard du Général Leclerc, 92110 Clichy, France. mohamed.bouattour@aphp.fr
Keywords Hepatocellular carcinoma; Antiangiogenic therapies; Sorafenib; Predictive biomarkers; Prognosis biomarkers; Functional imaging
Core Tip The approval of sorafenib in advanced hepa-tocellular carcinoma is based on the positive results of two large randomized phase Ⅲ clinical trials. The inter- and intra-individual variability regarding tumor response and clinical outcome highlighted the unmet need of effective biomarkers of response. These biomarkers could be useful for monitoring treatment activity, detecting early resistance to treatment and identifying patients who would more likely benefit from treatment. An overview of prognostic/predictive biomarkers of sorafenib in hepatocellular carcinoma is discussed in this review.
Publish Date 2015-09-15 18:11
Citation Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015; 7(20): 2245-2263
Url http://www.wjgnet.com/1948-5182/full/v7/i20/2245.htm
DOI http://dx.doi.org/10.4254/wjh.v7.i20.2245
Full Article (PDF) WJH-7-2245.pdf
Full Article (Word) WJH-7-2245.doc
Revised Manuscript 15818-Review.doc
Peer-review Report 15818-Peer-review(s).pdf
Answering Reviewers 15818-Answering reviewers.pdf
Scientific Misconduct Check 15818-Scientific misconduct check.pdf
Scientific Editor Work List 15818-Scientific editor work list.pdf
Audio Core Tip 15818-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 15818-Conflict-of-interest statement.pdf
Copyright License Agreement 15818-Copyright assignment.pdf